Access to Anti-Obesity Medication for Medicare and Medicaid

By Rene Pretorius

December 9, 2024

The Biden administration’s proposal to expand anti-obesity medication coverage under Medicare and Medicaid focuses on improving access to these essential treatments for millions of Americans. With obesity affecting a large portion of the population, this initiative aims to tackle significant variations in access, cost, and coverage challenges.

Currently, millions of Americans struggle with obesity, yet access to effective anti-obesity medications is limited due to high costs and restrictive coverage policies. The proposed rule aims to expand access to these medications for approximately 3.4 million Medicare enrollees and 4 million Medicaid enrollees who are classified as obese, defined by a BMI of 30 kg/m² or higher. The out-of-pocket costs for anti-obesity medications can be prohibitively expensive, often exceeding $1,000 per month. This financial barrier prevents many individuals from accessing these life-saving treatments

Interventions to Overcome Low Anti-obesity Medication Coverage

Expanded Coverage:

The proposed rule would mandate that Medicare and Medicaid cover anti-obesity medications, significantly broadening access to these drugs. This expanded coverage includes medications like Wegovy (semaglutide), Ozempic (semaglutide), and Zepbound (tirzepatide).

Reduced Out-of-Pocket Costs:

The new proposal could reduce out-of-pocket costs for these prescription medications by as much as 95% for some Medicare enrollees. This change will make treatments more affordable and accessible.

Comprehensive Cost-Lowering Agenda:

The Biden administration is focused on a broader agenda to lower drug costs, which includes a drug price negotiation program and increased market competition. For example, the administration has successfully negotiated reduced prices for the first ten prescription drugs under Medicare, with savings ranging from 38% to 79% starting in 2026.

Addressing Health Disparities:

The expanded coverage will help reduce health disparities. It will particularly benefit low-income patients and Black and Hispanic individuals who often face barriers to accessing these essential medications.

Regulatory Changes:

The proposal would also tackle barriers to accessing care, such as inappropriate use of prior authorization. Notably, Medicare Advantage plans often reverse denials upon appeal, indicating that many enrollees might be missing out on necessary care due to initial rejections.

Financial Implications and Potential Opposition

The expanded coverage is projected to cost taxpayers up to $35 billion over the next decade. This raises concerns among proponents of reduced government spending. Potential opposition could arise from figures such as Robert F. Kennedy Jr., the nominated Head of the Department of Health and Human Services under the incoming administration.

In summary, the Biden administration’s proposal is a significant step towards enhancing access to anti-obesity medications by expanding coverage under Medicare and Medicaid, reducing out-of-pocket costs, and addressing broad cost and access challenges through comprehensive policy changes. By improving access to anti-obesity medications, we can help millions of individuals lead healthier lives.

Reference url

Recent Posts

oral health Africa
    

Oral Health in Africa: Promoting Collaborative Solutions

🦷 Is oral health taking a back seat in public health discussions in Africa?

A new article reveals alarming statistics about the high prevalence of untreated dental diseases across the continent and a critical shortage of oral health professionals. It emphasizes the urgent need for collaborative action among healthcare providers and policy-makers to integrate oral health into broader public health frameworks.

Discover how strengthening partnerships can pave the way for improved health outcomes and resource allocation in oral health.

#SyenzaNews #globalhealth #HealthEconomics

tislelizumab NSCLC treatment
        

Early Benefit Assessment of Tislelizumab NSCLC Treatment: Insights and Implications

🧐 How is the evolving treatment landscape for NSCLC affecting patient access to tislelizumab?

The German Federal Joint Committee (G-BA) has launched an early benefit assessment for tislelizumab as a second-line treatment for adults with advanced NSCLC. This assessment notably focuses on PD-L1 negative patients and highlights the need for additional data to substantiate its value amidst a shifting emphasis on first-line immunotherapy.

Explore the nuances of this assessment and its implications for future research and market access in the full article.

#SyenzaNews #oncology #MarketAccess

colorectal cancer screening
    

Advances in Colorectal Cancer Screening: Access and Cost

🚀 Is blood-based screening redefining colorectal cancer detection?

The Shield blood test offers a non-invasive alternative to colonoscopy—boosting screening uptake, but raising questions around effectiveness and value.

🔍 Discover how this innovation could reshape patient care, payer strategy, and health system costs.

#SyenzaNews #HealthcareInnovation #CostEffectiveness #DigitalTransformation

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.